Aranzazu Campo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2250890/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest. Chest, 2007, 132, 1932-1938.	0.4	385
2	Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 252-260.	2.5	207
3	Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1378-1383.	2.5	163
4	Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. European Respiratory Journal, 2011, 38, 359-367.	3.1	154
5	Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. Development and Validation of the COPD Lung Cancer Screening Score. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 285-291.	2.5	138
6	Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients. European Respiratory Journal, 2007, 30, 223-231.	3.1	132
7	Comparing algorithms for automated vessel segmentation in computed tomography scans of the lung: the VESSEL12 study. Medical Image Analysis, 2014, 18, 1217-1232.	7.0	131
8	Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. European Respiratory Journal, 2010, 35, 95-104.	3.1	120
9	Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 924-931.	2.5	90
10	Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study. Respiratory Medicine, 2013, 107, 702-707.	1.3	50
11	Factors determining early adherence to a lung cancer screening protocol. European Respiratory Journal, 2007, 30, 532-537.	3.1	49
12	The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. Lung Cancer, 2016, 97, 28-34.	0.9	45
13	Gender and Chronic Obstructive Pulmonary Disease in High-Risk Smokers. Respiration, 2006, 73, 306-310.	1.2	43
14	Surfactant Protein D, a Marker of Lung Innate Immunity, Is Positively Associated With Insulin Sensitivity. Diabetes Care, 2010, 33, 847-853.	4.3	38
15	Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT. Lung Cancer, 2016, 97, 81-86.	0.9	34
16	Emphysema Presence, Severity, and Distribution Has Little Impact on the Clinical Presentation of a Cohort of Patients With Mild to Moderate COPD. Chest, 2011, 139, 36-42.	0.4	29
17	Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. Chest, 2017, 151, 358-365.	0.4	29
18	Low-dose Volumetric Computed Tomography for Quantification of Emphysema in Asymptomatic Smokers Participating in an Early Lung Cancer Detection Trial. Journal of Thoracic Imaging, 2009, 24, 206-211.	0.8	27

Aranzazu Campo

#	Article	IF	CITATIONS
19	Emphysema phenotypes and lung cancer risk. PLoS ONE, 2019, 14, e0219187.	1.1	22
20	Obstructive Sleep Apnea Severity Is Associated with Left Ventricular Mass Independent of Other Cardiovascular Risk Factors in Morbid Obesity. Journal of Clinical Sleep Medicine, 2013, 09, 1165-1171.	1.4	21
21	Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2013, 8, e65593.	1.1	20
22	Telomere length, COPD and emphysema as risk factors for lung cancer. European Respiratory Journal, 2017, 49, 1601521.	3.1	19
23	Catathrenia: respiratory disorder or parasomnia?. Sleep Medicine, 2015, 16, 827-830.	0.8	17
24	Pulmonary arterial enlargement predicts long-term survival in COPD patients. PLoS ONE, 2018, 13, e0195640.	1.1	13
25	Prevalence and burden of bronchiectasis in a lung cancer screening program. PLoS ONE, 2020, 15, e0231204.	1.1	13
26	Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respiratory Research, 2017, 18, 175.	1.4	11
27	Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Research, 2021, 7, 00773-2020.	1.1	10
28	Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of EGF, IL-15, IL-8 and IL-1ra. PLoS ONE, 2013, 8, e60260.	1.1	9
29	Trabecular bone score in active or former smokers with and without COPD. PLoS ONE, 2019, 14, e0209777.	1.1	6
30	FDG Uptake and the Diagnostic Yield of Transbronchial Needle Aspiration. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 7-14.	0.8	5
31	<p>Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD</p> . International Journal of COPD, 2020, Volume 15, 1823-1829.	0.9	5
32	Seudoaneurisma de arteria bronquial y hematoma mediastÃnico tras EBUS-TBNA. Archivos De Bronconeumologia, 2021, 57, 142-143.	0.4	5
33	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2010, 138, 461-462.	0.4	2
34	The potential value of FRAX index and bone turnover markers to identify osteoporosis in COPD patients. , 2015, , .		0
35	Factors determining the presence of osteoporosis in active and former smokers. , 2016, , .		0
36	Bone attenuation on chest computed tomography correlates with bone mineral density on densitometry in patients with emphysema and COPD. , 2016, , .		0

#	Article	IF	CITATIONS
37	In active and former smokers with CT detected emphysema but without airway obstruction, the presence of an abnormal DLco is associated with a worse clinical presentation. , 2016, , .		0
38	Pulmonary artery diameter and nocturnal hypoxemia in smokers with/without COPD , 2018, , .		0
39	Prevalence and burden of bronchiectasis in a lung cancer screening program. , 2020, 15, e0231204.		0
40	Prevalence and burden of bronchiectasis in a lung cancer screening program. , 2020, 15, e0231204.		0
41	Prevalence and burden of bronchiectasis in a lung cancer screening program. , 2020, 15, e0231204.		0
42	Prevalence and burden of bronchiectasis in a lung cancer screening program. , 2020, 15, e0231204.		0